PROM1 and retinal disorder: Since both CD133+ and CD34+ cells have been successfully applied in cell therapies for retinopathy, CD133+CD34+ cells were directly applied in the present study (Kanji et al., 2014; Fadini et al., 2017; Rong et al., 2018).